GLP-1s may cut can­cer risk; Gyre’s stock falls af­ter hep B da­ta and of­fer­ing

Plus, news about Sanofi, Servi­er, BioNo­va, Ar­cutis, Roche, Satel­los Bio­science, Fore Bio­ther­a­peu­tics, Cin­clus Phar­ma and Zen­ti­va:

GLP-1 drugs could cut can­cer risk: An aca­d­e­m­ic, ob­ser­va­tion­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER